1. Academic Validation
  2. The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate

The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate

  • Bioorg Med Chem Lett. 2001 Apr 9;11(7):895-8. doi: 10.1016/s0960-894x(01)00078-6.
S J Macdonald 1 M D Dowle L A Harrison P Shah M R Johnson G G Inglis G D Clarke R A Smith D Humphreys C R Molloy A Amour M Dixon G Murkitt R E Godward T Padfield T Skarzynski O M Singh K A Kumar G Fleetwood S T Hodgson G W Hardy H Finch
Affiliations

Affiliation

  • 1 Medicinal Chemistry 2, GlaxoWellcome Medicines Research Centre, Stevenage, UK. sjfm5947@glaxowellcome.co.uk
Abstract

The discovery of a potent intracellular inhibitor of human neutrophil Elastase which is orally active and has a long duration of action is described. The pharmacodynamic and pharmacokinetic properties of a trans-lactam development candidate, GW311616A, are described.

Figures
Products